Disclosure Statement: The authors have nothing to disclose
Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials
Article first published online: 28 MAR 2011
© 2011 The Authors. obesity reviews © 2011 International Association for the Study of Obesity
Volume 12, Issue 5, pages e338–e347, May 2011
How to Cite
Kramer, C. K., Leitão, C. B., Pinto, L. C., Canani, L. H., Azevedo, M. J. and Gross, J. L. (2011), Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obesity Reviews, 12: e338–e347. doi: 10.1111/j.1467-789X.2010.00846.x
Funding: This study was supported in part by Projeto de Núcleos de Excelência do Ministério de Ciência e Tecnologia, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ 576627-2008-9), and Fundo de Incentivo a Pesquisa of Hospital de Clínicas de Porto Alegre (GPPG 09023). C.K.K is a recipient of a grant from Projeto Nacional de Pós-Doutorado no País (PNPD 03021/09-2). The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
- Issue published online: 19 APR 2011
- Article first published online: 28 MAR 2011
- Received 6 October 2010; revised 20 November 2010; accepted 22 November 2010
- Adverse events;
Topiramate was associated with weight loss in clinical trials. We summarize the evidence on the efficacy and safety of topiramate in the treatment of overweight/obesity. The databases Medline, Embase, and Cochrane were searched. Randomized controlled studies with at least 16 weeks of duration that report the effect of topiramate on weight loss and adverse events were eligible for inclusion. Ten studies were included (3320 individuals). Patients treated with topiramate lost an average of 5.34 kg (95% confidence interval [95%CI]−6.12 to −4.56) of additional weight as compared with placebo. According to meta-regression analysis, treatment duration and dosage were associated with the efficacy of topiramate treatment. Evaluating trials using topiramate 96–200 mg day−1, the weight loss was higher in trials with >28 weeks of duration (−6.58 kg [95%CI −7.48 to −5.68]) than in trials with ≤28 weeks (−4.11 kg [95%CI −4.92 to −3.30]). Data of 6620 individuals were available for adverse events evaluation and those more frequently observed were paraesthesia, taste impairment and psychomotor disturbances. The odds ratio for adverse events leading to topiramate withdrawal was 1.94 (95%CI 1.64–2.29) compared with the control group. In conclusion, topiramate might be a useful adjunctive therapeutic tool in the treatment of obesity as long as proper warnings about side effects are considered.